Abstract
Leptin has emerged as a major regulator of body adiposity. The majority of humans with obesity have a resistance to leptin. Human and rodent studies indicate that the major cause of this resistance arises from an impaired ability of leptin to cross the blood-brain barrier, with lesser roles played by receptor and post-receptor defects. Evidence from baboons living in the wild is consistent with the hypothesis that during most of evolution serum levels of leptin were much lower than those currently considered normal. Leptin may have evolved to signal to the brain when caloric reserves were adequate to engage in reproductive and other behaviors not immediately concerned with acquisition of calories. The leptin transporter is a regulated system, with the rate of transport being increased by alpha-1 adrenergic agents and decreased by starvation. Impaired regulation of the transporter or impairments in transporter production could underlie the resistance caused by transporter defects. Evolutionary pressures would not have selected against such impairments if leptin levels were lower than those typically seen in Western society. A model that could explain how leptin transporter resistance can be acquired is presented.
Keywords: leptin,, obesity,, blood-brain barrier,, cerebrospinal fluid,, resistance,, transport
Current Pharmaceutical Design
Title: Is Obesity a Disease of the Blood-Brain Barrier? Physiological, Pathological, and Evolutionary Considerations
Volume: 9 Issue: 10
Author(s): William A. Banks
Affiliation:
Keywords: leptin,, obesity,, blood-brain barrier,, cerebrospinal fluid,, resistance,, transport
Abstract: Leptin has emerged as a major regulator of body adiposity. The majority of humans with obesity have a resistance to leptin. Human and rodent studies indicate that the major cause of this resistance arises from an impaired ability of leptin to cross the blood-brain barrier, with lesser roles played by receptor and post-receptor defects. Evidence from baboons living in the wild is consistent with the hypothesis that during most of evolution serum levels of leptin were much lower than those currently considered normal. Leptin may have evolved to signal to the brain when caloric reserves were adequate to engage in reproductive and other behaviors not immediately concerned with acquisition of calories. The leptin transporter is a regulated system, with the rate of transport being increased by alpha-1 adrenergic agents and decreased by starvation. Impaired regulation of the transporter or impairments in transporter production could underlie the resistance caused by transporter defects. Evolutionary pressures would not have selected against such impairments if leptin levels were lower than those typically seen in Western society. A model that could explain how leptin transporter resistance can be acquired is presented.
Export Options
About this article
Cite this article as:
Banks A. William, Is Obesity a Disease of the Blood-Brain Barrier? Physiological, Pathological, and Evolutionary Considerations, Current Pharmaceutical Design 2003; 9 (10) . https://dx.doi.org/10.2174/1381612033455350
DOI https://dx.doi.org/10.2174/1381612033455350 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of the Metabolism of Polyunsaturated Fatty Acids and Butyrate in Colon Cancer Cells
Current Pharmaceutical Biotechnology Role of Sulfur Containing Amino Acids as an Adjuvant Therapy in the Prevention of Diabetes and its Associated Complications
Current Diabetes Reviews Gene therapy for Multiple Myeloma
Current Gene Therapy Platelet Activating Factor/Platelet Activating Factor Receptor Pathway as a Potential Therapeutic Target in Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Fc Receptor-Mediated Immune Responses: New Tools But Increased Complexity in HIV Prevention
Current HIV Research Potential of Peptide-Based Enhancers for Transdermal Delivery
Current Pharmaceutical Design Therapeutic Potential of Targeting the Endocannabinoids: Implications for the Treatment of Obesity, Metabolic Syndrome, Drug Abuse and Smoking Cessation
Current Medicinal Chemistry Editorial [ Receptor for Advanced Glycation Endproducts (RAGE): Coming Full Circle in Unraveling the Pathogenesis of Chronic Disease Guest Editor: Ann Marie Schmidt ]
Current Molecular Medicine Immunoregulation Through 1,25-Dihydroxyvitamin D 3 and its Analogs
Current Drug Targets - Inflammation & Allergy Biopterin Analogues: Novel Nitric Oxide Synthase Inhibitors with Immunosuppressive Action
Current Drug Metabolism A Novel Integrase Targeting Agent to Explore the Future Prospective of HIV Eradication: Dolutegravir
Current HIV Research Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update
Current Neuropharmacology Fc Receptor Signaling in Leukocytes: Role in Host Defense and Immune Regulation
Current Immunology Reviews (Discontinued) Lipoamino Acid Prodrugs of Paclitaxel: Synthesis and Cytotoxicity Evaluation on Human Anaplastic Thyroid Carcinoma Cells
Current Cancer Drug Targets Clinical Pattern and Causality Assessment of Drug-induced Cutaneous Reactions in a Tertiary Care Hospital in India: A Prospective Study
Current Drug Safety Reduction of eNOS in Vascular Smooth Muscle by Salt Independently of Hypertension
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Plant Phenylpropanoids as Emerging Anti-Inflammatory Agents
Mini-Reviews in Medicinal Chemistry The Spectrum of Nimesulide-Induced-Hepatotoxicity. An Overview
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Anti-Oxidant
Current Bioactive Compounds Fungal Gene-Encoded Peptidase Inhibitors
Current Medicinal Chemistry